Status:
COMPLETED
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Lead Sponsor:
Eli Lilly and Company
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
6-64 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus. There are 2 parts to this study. Part A is investigating how the body pro...
Eligibility Criteria
Inclusion
- Are male or female participants aged 6-64 with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
- Have a glycated hemoglobin (HbA1c) less than (\<)10.0 percent (%)
Exclusion
- Receiving any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 12 months prior to screening
- More than one episode of severe hypoglycaemia in the last 6 months
- Presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, proliferative retinopathy, uncontrolled celiac disease, uncontrolled hyperthyroidism or hypothyroidism, or adrenal insufficiency
- Have obvious clinical signs or symptoms of liver disease
- Have a history of renal impairment
Key Trial Info
Start Date :
March 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 14 2019
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03465878
Start Date
March 26 2018
End Date
November 14 2019
Last Update
June 18 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
LMC Endocrinology Centres Ltd.
Toronto, Ontario, Canada, M4G 3E8
2
Kinderkrankenhaus auf der Bult
Hanover, Lower Saxony, Germany, 30173